CAS: 85175-67-3; 3-(3-((3,4-Dimethoxyphenethyl)(Methyl)Amino)Propyl)-7,8-Dimethoxy-4,5-Dihydro-1H-Benzo[d]Azepin-2(3H)-One

上下游产品

CAS号85175-60-6 1-[7,8dimethoxy... | CAS号50-00-0 甲醛 | CAS号85175-76-4 1-[7,8-dimethox... | CAS号36770-74-8 N-甲基l-N-(3-氯丙基)... | CAS号20925-64-8 7,8-二甲氧基-1,3,4,... | CAS号93-40-3 3,4-二甲氧基苯乙酸 | CAS号73942-87-7 7,8-二甲氧基-1,3-二氢... | CAS号85175-59-3 7,8-二甲氧基-3-(3-氯... | CAS号73954-34-4 Ivabradine impu... | CAS号10313-60-7 (3,4-二甲氧基苯基)乙酰氯

📜1-[7,8Dimethoxy-1,3-Dihydro-2H-3-Benzazepin-2-On-3-Yl]-3-[n-Methyl-N-(2-{3,4-Dimethoxy-Phenyl}-Ethyl)-Amino]-Propane置于palladium On Activated Charcoal 氢气体系中,用 溶剂黄146 作为反应溶剂,化学反应 10.0H,反应生成 扎替雷定
参考文献:特定的缓动剂.1.取代的苯并ze庚因酮的化学,药理学和结构-活性关系,这是一类具有抗缺血特性的新型化合物.
标题:特定的缓动剂.1.取代的苯并ze庚因酮的化学,药理学和结构-活性关系,这是一类具有抗缺血特性的新型化合物.
摘要:通过用各种杂环系统取代亲脂性α-异丙基乙腈部分对钙拮抗剂维拉帕米(1)进行结构修饰,导致了一类新型的心血管化合物,其特点是具有特定的缓动心律活动.这些药物可降低心律,而不会结合经典的钙通道或β-肾上腺素受体,而是与窦房结的结构发生特异性相互作用.因此,它们也被称为窦房结抑制剂.原型法利帕米(2)已通过进一步处理邻苯二甲moiety部分进行了进一步优化.这导致了第二代特定的缓动性药物,这些药物具有增强的功效,并以苯并ze庚因衍生物ul-Fs 49(4)为代表,选择性地延长了作用时间.这类新型化合物中的结构活性关系揭示了活性对芳环的取代方式,中心氮原子的性质以及连接的烷基链长度的显着依赖性.苯并ze庚酮环对缓动性活动的关键作用可以通过其对整体分子构象的特殊影响来最好地解释.
DOI:10.1021/jm00167A033

专利信息

专利号:US-2014315720-A1
优先权日:2012-10-24
标 题 :Polysaccharide ester microspheres and methods and articles relating thereto
发明人：FALLON DENIS G; GARRETT THOMAS S; KIZER LAWTON E; ZAZZARA KAREN L; COMBS MICHAEL T; JOHNSON RICHARD K; DEHART GARY
权利人:CELANESE ACETATE LLC
摘要:A method for producing a polysaccharide ester microsphere may include forming a polysaccharide ester product from a polysaccharide synthesis, wherein the polysaccharide ester product comprises a polysaccharide ester and a solvent; diluting the polysaccharide ester product, thereby yielding a polysaccharide ester dope; and forming a plurality of polysaccharide ester microspheres from the polysaccharide ester dope. Suitable polysaccharides may include, but are not limited to, starch, cellulose, hemicellulose, algenates, chitosan, and any combination thereof. Esters thereof may be organic esters (e.g., acetate and the like), inorganic esters (e.g., sulfonates and the like), or combinations thereof. Further, the solids conent of the polysaccharide ester dope, in some instances, may be greater than about 16 wt %.